接受免疫调节药物治疗的多发性硬化症患者接种新型冠状病毒疫苗后的体液免疫和细胞免疫分析。
Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs.
作者信息
Meca-Lallana Virginia, Esparcia-Pinedo Laura, Aguirre Clara, Díaz-Pérez Carolina, Gutierrez-Cobos Ainhoa, Sobrado Mónica, Carabajal Estefanía, Río Beatriz Del, Ropero Noelia, Villagrasa Ramón, Vivancos José, Sanchez-Madrid Francisco, Alfranca Arantzazu
机构信息
Demyelinating Diseases Unit, Neurology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, Spain.
Immunology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, Spain.
出版信息
Clin Immunol Commun. 2023 Dec;3:6-13. doi: 10.1016/j.clicom.2023.02.001. Epub 2023 Feb 4.
Abstract
We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vaccination. Although DMTs such as fingolimod and anti-CD20+ treatments prevented patients from developing a robust humoral response to the vaccine, most of them were still able to develop a cellular response, which could be crucial for long-term immunity. It is probably advisable that all MS patients take additional/booster doses to increase their humoral and/or cellular immune response to SARS-CoV-2.
摘要
我们通过测量接受不同疾病修正治疗的多发性硬化症患者体内针对不同SARS-CoV-2肽段的特异性IgG滴度和T细胞反应性，分析了对SARS-CoV-2疫苗接种的免疫反应。在纳入的88名患者中，72名在接种疫苗后出现了任何一种免疫反应。虽然诸如芬戈莫德和抗CD20+治疗等疾病修正治疗阻止患者对疫苗产生强烈的体液反应，但他们中的大多数人仍能够产生细胞反应，这可能对长期免疫至关重要。所有多发性硬化症患者可能都需要接种额外剂量/加强剂量疫苗，以增强其对SARS-CoV-2的体液和/或细胞免疫反应。
相似文献
1
Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs.接受免疫调节药物治疗的多发性硬化症患者接种新型冠状病毒疫苗后的体液免疫和细胞免疫分析。
Clin Immunol Commun. 2023 Dec;3:6-13. doi: 10.1016/j.clicom.2023.02.001. Epub 2023 Feb 4.
2
Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.多发性硬化症患者对 SARS-CoV-2 mRNA 疫苗接种的体液和细胞免疫反应：以色列 3 剂疫苗接种后的多中心经验。
Front Immunol. 2022 Apr 1;13:868915. doi: 10.3389/fimmu.2022.868915. eCollection 2022.
3
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.一项针对多种疾病修正治疗药物治疗的多发性硬化症患者对 COVID-19 加强疫苗接种的细胞免疫反应的前瞻性研究。
J Neurol. 2023 May;270(5):2380-2391. doi: 10.1007/s00415-023-11575-8. Epub 2023 Mar 18.
4
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.SARS-CoV-2 mRNA 疫苗未能在接受芬戈莫德治疗的多发性硬化症患者中引发体液和细胞免疫应答。
J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):960-971. doi: 10.1136/jnnp-2022-329395. Epub 2022 Jul 14.
5
Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies.接受疾病修正治疗的多发性硬化症患者对SARS-CoV-2疫苗接种的短期和长期体液免疫及细胞免疫反应
Vaccines (Basel). 2023 Apr 3;11(4):786. doi: 10.3390/vaccines11040786.
6
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study.对撒丁岛多发性硬化症患者接种 SARS-CoV-2 疫苗后的体液反应进行横断面分析，一项随访研究。
Front Immunol. 2022 Aug 18;13:946356. doi: 10.3389/fimmu.2022.946356. eCollection 2022.
7
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.在接受抗 CD20 治疗和鞘氨醇-1-磷酸受体调节剂治疗的 MS 患者中，序贯接种 SARS-CoV-2 疫苗后的纵向适应性免疫反应。
Mult Scler Relat Disord. 2023 Feb;70:104484. doi: 10.1016/j.msard.2022.104484. Epub 2022 Dec 28.
8
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.抗 CD20 治疗的多发性硬化症患者对 SARS-CoV-2 疫苗接种的体液和 T 细胞免疫应答不一致。
EBioMedicine. 2021 Nov;73:103636. doi: 10.1016/j.ebiom.2021.103636. Epub 2021 Oct 16.
9
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.深入分析特立氟胺或阿仑单抗治疗多发性硬化症患者对 COVID-19mRNA 疫苗接种的长期体液和细胞免疫反应。
Mult Scler Relat Disord. 2023 Apr;72:104616. doi: 10.1016/j.msard.2023.104616. Epub 2023 Mar 12.
10
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.奥瑞珠单抗和芬戈莫德治疗多发性硬化症患者对 mRNA SARS-CoV-2 疫苗接种的 6 个月体液反应。
Mult Scler Relat Disord. 2022 Apr;60:103724. doi: 10.1016/j.msard.2022.103724. Epub 2022 Mar 4.
引用本文的文献
1
Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination.多发性硬化症的疾病修正治疗对免疫细胞和对 COVID-19 疫苗接种反应的影响。
Front Immunol. 2024 Jul 15;15:1416464. doi: 10.3389/fimmu.2024.1416464. eCollection 2024.
2
Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine.血液中CD8 + 初始T细胞可识别对SARS-CoV-2疫苗有最佳细胞反应高可能性的多发性硬化症患者。
Vaccines (Basel). 2023 Aug 22;11(9):1399. doi: 10.3390/vaccines11091399.
本文引用的文献
1
CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects.接种疫苗后健康和 COVID-19 康复受试者 CD4+ T 细胞免疫特异性变化。
Front Immunol. 2022 Jan 19;12:755891. doi: 10.3389/fimmu.2021.755891. eCollection 2021.
2
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.西尼莫德或芬戈莫德治疗患者的 COVID-19 感染：病例系列。
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 30;9(1). doi: 10.1212/NXI.0000000000001092. Print 2021 Nov.
3
The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021.免疫实践咨询委员会关于 COVID-19 疫苗加强针和额外基础针的临时建议-美国，2021 年。
MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1545-1552. doi: 10.15585/mmwr.mm7044e2.
4
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.抗 CD20 治疗的多发性硬化症患者对 SARS-CoV-2 疫苗接种的体液和 T 细胞免疫应答不一致。
EBioMedicine. 2021 Nov;73:103636. doi: 10.1016/j.ebiom.2021.103636. Epub 2021 Oct 16.
5
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.多发性硬化症患者接种辉瑞 BNT162b2 COVID19 疫苗后的体液免疫反应：长达 6 个月的横断面研究。
J Neuroimmunol. 2021 Dec 15;361:577746. doi: 10.1016/j.jneuroim.2021.577746. Epub 2021 Oct 9.
6
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.抗 CD20 治疗的多发性硬化症患者接种 SARS-CoV-2 mRNA 疫苗后的细胞和体液免疫反应。
Nat Med. 2021 Nov;27(11):1990-2001. doi: 10.1038/s41591-021-01507-2. Epub 2021 Sep 14.
7
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis.尽管在多发性硬化症中进行了B细胞清除治疗，但仍产生了针对严重急性呼吸综合征冠状病毒2的体液和细胞免疫记忆。
iScience. 2021 Sep 24;24(9):103078. doi: 10.1016/j.isci.2021.103078. Epub 2021 Sep 2.
8
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.两剂 SARS-CoV-2 疫苗接种可诱导针对新出现的 SARS-CoV-2 关切变异株的强大免疫应答。
Nat Commun. 2021 Aug 17;12(1):5061. doi: 10.1038/s41467-021-25167-5.
9
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.抗 CD20 治疗可降低多发性硬化或视神经脊髓炎谱系疾病患者对 SARS-CoV-2 的体液免疫应答。
J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):24-31. doi: 10.1136/jnnp-2021-326904. Epub 2021 Aug 2.
10
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.第二次接种BNT162b2或ChAdOx1后刺突抗体水平下降。
Lancet. 2021 Jul 31;398(10298):385-387. doi: 10.1016/S0140-6736(21)01642-1. Epub 2021 Jul 17.
Zotero 插件